Dutt Braham, Choudhary Manjusha, Budhwar Vikas
Maharishi Dayanand University, Department of Pharmaceutical Sciences, Haryana, India
Kurukshetra University, Institute of Pharmaceutical Sciences, Department of Pharmacy, Kurukshetra, India
Turk J Pharm Sci. 2022 Apr 29;19(2):220-231. doi: 10.4274/tjps.galenos.2020.78700.
Co-crystallization (CCs) is a less studied phenomenon related to its applicability and reliability as it is directly related to the generation of newer multicomponent solids like co-crystals (CS), eutectic, salts or solid solutions . having improved physicochemical properties compared to their pure components. Further, the design and structural aspects of these multicomponent systems remain hindered compared to other techniques such as nanotechnology or solid dispersion. CC is a newer technique to modify the physicochemical as well as pharmaceutical characteristics of various drugs having issues like solubility, stability, . without altering or hindering their pharmacological activities. For drug delivery purpose, CC process has numerous advantages over nanotechnology and solid dispersion drug delivery techniques. CCs can modify the physicochemical properties of active pharmaceutical ingredients (API) have issues like sensitivity toward environmental hazards like temperature, moisture, or photostability issues. The availability of large numbers of conformers makes this technique favorable for the researchers in designing CS of newer and older. Although, solid dispersion and nanotechnology techniques are being utilized to a larger extent still there are some drawbacks of these techniques like stability, toxicological factors and protection from environmental factors need to be considered, while the CCs process drastically modifies the various pharmaceutical parameters without altering the pharmacological properties of API's. Salts, design of CS, their methods of preparation, and their application in various fields with special emphasis on their applicability in the pharmaceutical industry.
共结晶(CCs)是一种较少被研究的现象,涉及其适用性和可靠性,因为它与新型多组分固体如共晶体(CS)、低共熔物、盐或固溶体的产生直接相关,与它们的纯组分相比,这些多组分固体具有改善的物理化学性质。此外,与纳米技术或固体分散等其他技术相比,这些多组分体系的设计和结构方面仍然受到阻碍。共结晶是一种更新的技术,用于改变各种存在溶解度、稳定性等问题的药物的物理化学以及药学特性,而不改变或阻碍它们的药理活性。出于药物递送目的,共结晶过程相对于纳米技术和固体分散药物递送技术具有许多优势。共结晶可以改变活性药物成分(API)的物理化学性质,这些活性药物成分存在对温度、湿度等环境危害敏感或光稳定性问题。大量构象异构体的存在使得该技术有利于研究人员设计新的和旧的共晶体。尽管固体分散和纳米技术在很大程度上仍在被使用,但这些技术仍存在一些缺点,如稳定性、毒理学因素以及需要考虑免受环境因素影响,而共结晶过程在不改变API药理性质的情况下极大地改变了各种药学参数。盐、共晶体的设计、它们的制备方法以及它们在各个领域的应用,特别强调它们在制药工业中的适用性。